Cerebral venous thrombosis after intravenous immunoglobulin therapy in immune thrombocytopenic purpura

P. V. Shiji; Chandni Radhakrishnan

doi:10.4103/ijccm.IJCCM_308_17

SEARCH WITHIN CONTENT

Online First

Cerebral venous thrombosis after intravenous immunoglobulin therapy in immune thrombocytopenic purpura

P. V. Shiji, Chandni Radhakrishnan

Keywords : Immune thrombocytopenic purpura, intravenous immunoglobulin, venous thrombosis

Citation Information : Shiji PV, Radhakrishnan C. Cerebral venous thrombosis after intravenous immunoglobulin therapy in immune thrombocytopenic purpura. Indian J Crit Care Med 2017; 21 (12):869-871.

DOI: 10.4103/ijccm.IJCCM_308_17

License: CC BY-ND 3.0

Published Online: 01-07-2013

ARTICLE
REFERENCES

Abstract

A common misconception is that immune thrombocytopenic purpura (ITP) causes only bleeding diathesis. From this case vignette of a young male with ITP who had cerebral venous thrombosis, we highlight the importance of considering venous thrombosis in such patients when they present with focal cerebral signs.

PDF Share

Psaila B, Petrovic A, Page LK, Menell J, Schonholz M, Bussel JB, et al. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): Study of 40 cases. Blood 2009;114:4777-83.
Takagi S, Suzuki I, Watanabe S. Risk of thromboembolism in patients with immune thrombocytopenia. J Hematol Thromboembolic Dis 2015;3:1-9.
Cotillon M, Lebas A, Blanc T, Schneider P, Vannier JP, Buchbinder N, et al. Cerebral venous thrombosis and immune thrombocytopenia in a 7-year-old girl: A fortuitous association?. Arch Pediatr 2014;21:1367-9.
Vucic S, Chong PS, Dawson KT, Cudkowicz M, Cros D. Thromboembolic complications of intravenous immunoglobulin treatment. Eur Neurol 2004;52:141-4.
Marie I, Maurey G, Hervé F, Hellot MF, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 2006;155:714-21.
Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events. Neurology 1994;44:223-6.
Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992;339:662-4.
Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000;65:30-4.
Ammann EM, Haskins CB, Fillman KM, Ritter RL, Gu X, Winiecki SK, et al. Intravenous immune globulin and thromboembolic adverse events: A systematic review and meta-analysis of RCTs. Am J Hematol 2016;91:594-605.
Kayyali HR, Abdelmoity AT, Morriss MC, Graf WD. Cerebral venous thrombosis after immune thrombocytopenic purpura and anti-D immune globulin therapy. J Child Neurol 2008;23:325-30.
Johannesdottir SA, Horváth-Puhó E, Dekkers OM, Cannegieter SC, Jørgensen JO, Ehrenstein V, et al. Use of glucocorticoids and risk of venous thromboembolism: A nationwide population-based case-control study. JAMA Intern Med 2013;173:743-52.

PDF Share